Abstract:Objective To study the effect of Lactobacillus paracasei N1115 on serum lipid and gut microbiota of dyslipidemias. And to explore the health effect of Lactobacillus paracasei N1115 on other aspect. Methods This is a randomized single‐blinded placebo‐controlled human intervention study. It has been approved by Biomedical ethics committee of Peking university, and the file number is IRB00001052‐14069. Dyslipidemias are recruited as subjects, and administered with Lactobacillus paracasei N1115 for 12 weeks. Blood sample and fecal sample was collected. Height, weight, body fat percentage, and bone mineral density was measured. Special questionnaire was designed to collect the information about the socioeconomics, diet, gastrointestinal function and sleep quality. By detecting the serum lipid, gut microbiota, gastrointestinal function, bone mineral density, body fat percentage and sleep quality, we can analyze the effect Lactobacillus paracasei N1115 has on the dyslipidemias' health. Data analysis method includes repeated measures analysis of variance, paired t test and rank correlated Wilcoxon test. Results TC concentration in serum increased 0.09 mmol/L in placebo group, but decreased 0.13 mmol/L in probiotics group through the intervention. Significant difference was found on TC between groups after intervention. LDL‐C concentration in serum increased 0.02 mmol/L in placebo group, but decreased 0.14mmol/L in probiotics group through the intervention. Significant difference was found on LDL‐C between groups after intervention, also on the change between groups with RMANOVA analyzed. FPG decreased 0.41 mmol/L in probiotics group significantly, but didn't in placebo group. Apo‐A1 decreased significantly in both groups, but no significant difference was found between groups. The relative abundance of Alistipes spp. and Fusobacterium spp. decreased significantly, and the relative abundance of Faecalibacterium spp. and Lactobacillus spp. increased significantly in placebo group. The relative abundance of Megamonas spp. Faecalibacterium spp. and Lactobacillus spp. increased significantly, the relative abundance of Bacteroides spp. and Phascolarctobacterium spp. decreased significantly in probiotics group. The Shannon index of gut microbiota decreased significantly from 2.335 to 2.158 in placebo group. The Chao1 index (117.015→131.164), Shannon index (2.293→2.469) of gut microbiota increased significantly, Simpson index (0.214→0.165) decreased significantly in probiotics group. Trunk fat mass decreased significantly in probiotics group (P=0.005), but didn't in placebo group. BMI, body fat percentage, bady fat mass, trunk fat percentage decreased significantly in both groups, but no significant difference was found between groups. Conclusion Lactobacillus paracasei N1115 can decrease LDL‐C level. It can increase the relative abundance of Megamonas spp., decrease that of Bacteroides spp. and Phascolarctobacterium spp. of dyslipidemias. It can significantly increase the abundance and diversity of gut microbiota of dyslipidemias. Support or Funding Information The study was designed by Professor. Yumei Zhang, and carried out by all the authors. The article was mainly written by Shengjie Tan, and assisted by Yingdong Zheng on biostatistics. Basic information and life style Basic information and life style Placebo Probiotics P Sex 0.951 a Male 12 (26.0) 12 (26.0) Female 35 (74.0) 34 (74.0) Age 56.3 ± 5.3 55.9 ± 5.4 0.671 b BMI 25.7 ± 3.5 25.3 ± 3.3 0.584 b Smoke 0.793 a Yes 8 (19.0) 10 (22.7) No 34 (81.0) 34 (77.3) Alcohol use 0.138 a Never 30 (73.2) 23 (52.3) Ever but not now 2 (4.9) 4 (9.1) Now 9 (22.0) 17 (38.6) Chi‐square test; Independent sample T test Change of blood lipid indicator Change of blood lipid indicators before and after intervention (χ̄±SD) Blood lipid indicator Placebo (n=47) Probiotics (n=46) Intervention Effects week 0 week 12 Change P a week 0 week 12 Change P a P b TC (mmol/L) 5.84 ± 0.78 5.93 ± 0.98 0.09 0.409 5.67 ± 0.63 5.55 ± 0.81 −0.13 0.244 0.068 TG (mmol/L) 1.92 ± 0.98 2.11 ± 1.74 0.20 0.312 1.92 ± 1.47 2.23 ± 2.37 0.31 0.171 0.846 HDL‐C (mmol/L) 1.35 ± 0.33 1.38 ± 0.37 0.03 0.240 1.36 ± 0.38 1.36 ±0.40 0.00 0.856 0.906 LDL‐C (mmol/L) 3.78 ± 0.72 3.81 ± 0.81 0.02 0.823 3.58 ± 0.58 3.44 ± 0.76 −0.14 0.155 0.034 Apo‐A1 (g/L) 1.72 ± 0.30 1.64 ± 0.30 −0.08 0.027 1.71 ± 0.39 1.63 ± 0.28 −0.08 0.031 0.854 Apo‐B (g/L) 1.14 ± 0.19 1.14 ± 0.18 0.00 0.979 1.10 ± 0.19 1.06 ± 0.20 −0.04 0.213 0.082 FPG (mmol/L) 5.59 ± 0.98 5.48 ± 2.35 −0.10 0.674 5.64 ± 1.58 5.23 ± 1.95 −0.41 0.001 0.769 TC:HDL‐C 4.53 ± 1.08 4.52 ± 1.14 −0.01 0.930 4.50 ± 1.43 4.40 ± 1.50 −0.11 0.409 0.777 LDL‐C:HDL‐C 2.94 ± 0.84 2.90 ± 0.85 −0.04 0.742 2.84 ± 0.93 2.69 ± 0.83 −0.16 0.099 0.343 AI 3.53 ± 1.08 3.52 ± 1.14 −0.01 0.930 3.50 ± 1.43 3.40 ± 1.50 −0.11 0.409 0.777 Difference between week 0 and week 12 by paired‐sample T test; Repeated measurement data analysis of variance Change of gut microbiota relative abundance at genus level Change of gut microbiota relative abundance at genus level [M(P 25 –P 75 )] Relative abundance week 0 week 12 Placebo Probiotics Placebo Probiotics Alistipes 0.68 (0.32–3.00) 0.92 (0.23–1.18) 0.43 (0.6–1.07) ** 0.74 (0.41–1.38) Bacteroides 27.57 (15.14–41.71) 31.68 (16.89–45.77) 23.10 (13.68–34.75) 17.55 (10.92–27.18) * Bifidobacteriuui 0.45 (0.18–2.16) 1.16 (0.30–1.89) 0.49 (0.23–0.94) 0.49 (0.27–1.30) Dialister 0.08 (0.06–0.57) 0.08 (0.05–0.72) 0.16 (0.06–0.56) 0.17 (0.11–0.94) Escherichia‐Shigella 0.13 (0.08–0.76) 0.20 (0.07–0.35) 0.16 (0.09–0.60) 0.24 (0.12–0.37) Faecalibacterium 9.43 (5.39–16.91) 10.42 (5.91–16.70) 24.58 (14.36–36.47) ** 20.49 (10.94–29.09) ** Fusobacterium 0.10 (0.06–0.79) 0.05 (0.02–0.08) 0.03 (0.01–0.07) ** 0.08 (0.03–0.24) Lachnospira 1.79 (0.81–4.71) 2.95 (1.65–4.59) 1.71 (0.59–4.46) 2.80 (1.63–4.44) Lactobacillus 0.11 (0.02–0.32) 0.13 (0.08–0.22) 0.47 (0.25–0.81) ** 0.56 (0.31–0.81) ** Megamonas 0.10 (0.07–0.33) 0.12 (0.08–0.23) 0.10 (0.07–0.18) 0.24 (0.13–1.95) ** Oscillibacter 0.40 (0.17–1.43) 0.25 (0.12–0.49) 0.33 (0.25–0.79) 0.38 (0.24–0.80) Parabacteroides 0.80 (0.53–1.61) 1.06 (0.58–1.24) 0.94 (0.43–1.54) 0.93 (0.68–1.17) Parasutterella 0.27 (0.11–1.42) 0.78 (0.09–1.82) 0.19 (0.09–0.80) 0.23 (0.11–0.69) Phascolarctobacterim 0.80 (0.22–2.05) 1.64 (0.50–2.27) 0.84 (0.34–1.83) 0.65 (0.17–1.15) * Prevotella 1.47 (1.17–5.19) 1.34 (0.71–2.41) 1.08 (0.71–3.69) 2.54 (1.28–18.25) Pseudobutyrivibrio 1.34 (0.38–2.34) 1.40 (0.78–3.37) 0.92 (0.37–1.91) 1.45 (1.01–2.75) Roseburia 0.53 (0.19–1.13) 0.63 (0.30–0.91) 0.42 (0.18–0.98) 0.51 (0.29–0.80) Ruminococcus 1.17 (0.81–3.87) 2.23 (0.99–3.73) 1.44 (0.81–3.18) 2.02 (1.21–4.10) Subdoligranulum 0.51 (0.18–1.03) 0.66 (0.23–1.56) 0.41 (0.18–0.74) 0.80 (0.26–1.28) Difference between week 0 and week 12 by non‐parameters Wilcoxon symbols test; P <0.05; P <0.01 Change of gut microbiota diversity Change of gut microbiota diversity group week Abundance Index Diversity Index ACE Chaol Shannon Simpson Placebo (n=25) 0 137.208 a 123.729 a 2.335 a 0.196 a 6 142.970 a 129.159 a 2.333 a 0.195 a 12 138.090 a 129.956 a 2.158 b 0.228 a Probiotics(n=20) 0 129.620 a 117.015 b 2.293 b 0.214 a 6 136.046 a 127.988 ab 2.421 ab 0.179 ab 12 137.368 a 131.164 a 2.469 a 0.165 b In same group, different letter (a, b) means the significant difference. ( P< .0.05)

Reply-Letter to the Editor: Cardiometabolic Benefits of Lacticaseibacillus Paracasei 8700:2: A Randomized Double-Blind Placebo-Controlled Trial

Cardiometabolic benefits of <i>Lacticaseibacillus paracasei</i> 8700:2: A randomized double-blind placebo-controlled trial

Cardiometabolic benefits of Lacticaseibacillus paracasei 8700:2 : A randomized double-blind placebo-controlled trial

Effect of Lacticaseibacillus casei LC2W Supplementation on Glucose Metabolism and Gut Microbiota in Subjects at High Risk of Metabolic Syndrome: A Randomized, Double-blinded, Placebo-controlled Clinical Trial

Effects of Lactobacillus paracasei N1115 on intestinal microbiota and serum lipid of dyslipidemias

Effects of Lactobacillus Paracasei N1115 on Dyslipidaemia: A Randomized Controlled Study

Effect of Lacticaseibacillus Paracasei K56 with Galactooligosaccharide Synbiotics on Obese Individuals: an in Vitro Fermentation Model.

Unconjugated and Secondary Bile Acid Profiles in Response to Higher-Fat, Lower-Carbohydrate Diet and Associated with Related Gut Microbiota: A 6-Month Randomized Controlled-Feeding Trial

Changes in the gut microbiota composition of healthy young volunteers after administration of Lacticaseibacillus rhamnosus LRa05: A placebo-controlled study

Effect of Lacticaseibacillus paracasei K56 with galactooligosaccharide synbiotics on obese individuals by in vitro fermentation model.

Effects of Lacticaseibacillus rhamnosus HA-114 probiotic supplementation on circulating IGFBP-2 levels during a calorie-restricted diet in overweight humans

Lacticaseibacillus paracasei 207-27 alters the microbiota–gut–brain axis to improve wearable device-measured sleep duration in healthy adults: a randomized, double-blind, placebo-controlled trial

Potential mechanisms underlying the ameliorative effect of <i>Lactobacillus paracasei</i> FZU103 on the lipid metabolism in hyperlipidemic mice fed a high-fat diet

Potential mechanisms underlying the ameliorative effect of Lactobacillus paracasei FZU103 on the lipid metabolism in hyperlipidemic mice fed a high-fat diet

Effect of Lacticaseibacillus paracasei strain Shirota Supplementation on Clinical Responses and Gut Microbiome in Parkinson's Disease

Effects of Lactobacillus supplementation on glycemic and lipid indices in overweight or obese adults: A systematic review and meta-analysis

Effect of Probiotics Lactobacillus Paracasei Subsp. Paracasei Zhang on Gut Microbiota Composition of Young People Living in Hainan

Impact of Lactocaseibacillus (Lactobacillus) paracasei sup. paracasei TISTR 2593 Probiotic Supplementation on the Gut Microbiome of Hypercholesterolemia Patients: A Randomized Controlled Trial

Plant-Derived Lactobacillus paracasei IJH-SONE68 Improves the Gut Microbiota Associated with Hepatic Disorders: A Randomized, Double-Blind, and Placebo-Controlled Clinical Trial

Effect of different doses of Lacticaseibacillus paracasei K56 on body fat and metabolic parameters in adult individuals with obesity: a pilot study